Hyderabad, India, February 25, 2014  

Dr. Reddy’s announces the Launch of Sumatriptan Injection USP, Autoinjector System

Hyderabad, India, February 25, 2014

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 mL, For Subcutaneous Use, a therapeutic equivalent generic version of IMITREX STATdose Pen® (sumatriptan succinate) 6 mg/0.5 mL in the US market on February 25, 2014, following the approval by the United States Food & Drug Administration (USFDA).

The IMITREX STATdose Pen® (sumatriptan succinate) brand and generic combined had U.S. sales of approximately $169 Million MAT for the most recent twelve months ending in December 2013 according to IMS Health*.

Dr. Reddy’s Sumatriptan Injection USP, Autoinjector System 6 mg/ 0.5 mL is available in a carton containing 2 single-dose prefilled syringes.

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets. For more information, log on to:

IMITREX STATdose Pen® is a registered trademark of Glaxo Group Limited.
*IMS National Sales Perspectives: Retail and Non-Retail MAT December 2013

For more information please contact:

Investors and Financial Analysts:
Kedar Upadhye at / +91-40-66834297
Saunak Savla at / +91-40-49002135
Milan Kalawadia (USA) at / +1 609-375-9831

SVS Chowdary at / +91-40-49002448